Search

Displaying results 3901 - 3910 of 9322 in total
  1. Drug

    Brilaroxazine

    go.drugbank.com/drugs/DB09226
    Investigational

    Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease … Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder.

  2. Drug

    Oxytetracycline

    go.drugbank.com/drugs/DB00595
    ApprovedInvestigationalVet approved

    A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.

  3. Drug

    Edotreotide gallium Ga-68

    go.drugbank.com/drugs/DB15494
    Approved

    Edotreotide gallium Ga-68 is an 8 amino acid peptide bound to the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).

  4. Drug

    Linaprazan glurate

    go.drugbank.com/drugs/DB21534
    Investigational

    The usage of the INN stem '-prazan' in the name indicates that Linaprazan glurate is a proton pump inhibitor, not dependent on acid activation. … to Gastroesophageal Reflux Disease (GERD)).

  5. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. … Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4).

    Categories: Increased T Lymphocyte Activation
  6. Drug

    Pegdinetanib

    go.drugbank.com/drugs/DB05931
    Investigational

    CT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis

  7. Drug

    Dioxybenzone

    go.drugbank.com/drugs/DB11221
    ApprovedWithdrawn

    Dioxybenzone is an approved sunscreen ingredient in concentrations up to 3% [L2525].

  8. Drug

    Otilonium

    go.drugbank.com/drugs/DB13500
    Investigational

    Mixtures: BROMURO DE OTILONIO + SIMETICONA 40MG + 200MG
  9. Drug

    Nedaplatin

    go.drugbank.com/drugs/DB13145
    ApprovedInvestigational

    Nedaplatin is a second generation platinum analog . It is less nephrotoxic than DB00515 but has proven equally effective. It was approved for use in Japan in 1995.

  10. Drug

    IMM101

    go.drugbank.com/drugs/DB15851
    Experimental

    Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells. … It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039].